Medicine and HealthNature Medicine
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
D. H. Ryan, I. Lingvay, et al.
Discover how semaglutide can transform weight management for adults with cardiovascular disease. This analysis of the SELECT trial showcases impressive long-term weight loss and anthropometric improvements, conducted by a team of experts including Donna H. Ryan and Ildiko Lingvay.
Related Publications
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Medicine and Health
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
D. H. Ryan, I. Lingvay, et al.
Medicine and Health
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
H. M. Colhoun, I. Lingvay, et al.
Medicine and Health
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
J. F. E. Mann, P. Rossing, et al.
Medicine and Health
Effects of Mediterranean diet during pregnancy on the onset of overweight or obesity in the offspring: a randomized trial
S. Coppola, L. Paparo, et al.
